Who Manufactures Gabapentin? Brand and Generic Makers

Gabapentin was originally developed by the pharmaceutical company Parke-Davis and sold under the brand name Neurontin. Pfizer now owns the Neurontin brand after acquiring Parke-Davis’s parent company Warner-Lambert in 2000. Since the core patent expired, dozens of generic manufacturers around the world produce gabapentin in various forms, and the generic versions account for the vast majority of prescriptions filled today. The manufacturing picture is broader than most people realize, stretching from large multinational companies to specialized facilities in India and China that produce the raw ingredient.

Neurontin and Its Origins

Parke-Davis, a historic American pharmaceutical company based in Detroit, developed gabapentin in the 1990s and received FDA approval in 1993 for use as an add-on treatment for partial seizures. The drug was marketed under the brand name Neurontin. Warner-Lambert, which owned Parke-Davis at the time, was acquired by Pfizer in 2000 in what was then one of the largest pharmaceutical mergers in history. Pfizer inherited the Neurontin brand and continued to market it aggressively, turning it into a blockbuster drug with annual sales that peaked at roughly $2.7 billion before generic competition arrived.

Neurontin’s core compound patent expired in 2004, opening the door for generic manufacturers. Pfizer still sells branded Neurontin, but it represents a tiny fraction of total gabapentin prescriptions. Most pharmacies now automatically dispense a generic version unless a prescriber specifically requests the brand, which rarely happens given the significant price difference.

Major Generic Manufacturers

The list of companies approved to manufacture generic gabapentin in the United States alone is long. The FDA’s Orange Book, which tracks approved drug products and their manufacturers, includes numerous companies with active approvals for gabapentin capsules, tablets, and oral solutions. Some of the largest and most commonly encountered include:

Teva Pharmaceutical Industries: One of the world’s largest generic drugmakers, headquartered in Israel. Teva was among the first to launch generic gabapentin after the patent expired.
Aurobindo Pharma: An India-based manufacturer with a large presence in the U.S. generic market, producing gabapentin in multiple dosage forms.
Amneal Pharmaceuticals: A major U.S.-based generic company that produces gabapentin capsules and tablets at facilities in the U.S. and India.
Zydus Pharmaceuticals: The U.S. arm of Zydus Lifesciences (formerly Cadila Healthcare), based in India.
Sun Pharmaceutical: Another large Indian manufacturer with extensive U.S. distribution.
Lupin Pharmaceuticals: Produces gabapentin in several strengths, with manufacturing facilities in India and the U.S.
Ascend Laboratories: A subsidiary of Alkem Laboratories, an Indian company with growing U.S. market share.
InvaGen Pharmaceuticals: A subsidiary of Cipla, one of India’s oldest pharmaceutical companies.
Apotex: A Canadian generic manufacturer with a significant global footprint.

This is far from exhaustive. Gabapentin is one of the most prescribed medications in the United States, ranking consistently among the top drugs by total prescriptions. An analysis of U.S. government databases found that gabapentin was one of the most common oral antiseizure medications in the generic supply chain.¹ That kind of volume attracts many manufacturers, because even thin profit margins per pill add up when you are producing hundreds of millions of doses annually.

Where the Active Ingredient Comes From

There is an important distinction between the companies whose names appear on your pill bottle and the facilities that actually synthesize the raw chemical. Gabapentin, like most generic drugs, has a supply chain that starts with the active pharmaceutical ingredient, commonly called the API. The API is the actual gabapentin molecule, which is then formulated into capsules, tablets, or liquid at a separate facility, often in a different country entirely.

The bulk of the world’s gabapentin API is manufactured in India and China. These two countries dominate API production for the global pharmaceutical industry in general, and gabapentin is no exception. Companies like Wavelength Pharmaceuticals, Jiangsu Enhua Pharmaceutical, and numerous smaller chemical manufacturers produce gabapentin API that is then shipped to formulation plants around the world. A “generic gabapentin made by Teva” might contain API synthesized in a Chinese chemical plant, formulated into capsules at a facility in India, and packaged for sale in New Jersey. Each step in that chain is subject to regulatory inspection by the FDA or its equivalent in the destination country, but the complexity means the supply chain has more links than most patients imagine.

This geographic concentration matters because disruptions at the API level can cascade. If a major API supplier shuts down for regulatory violations or a natural disaster, multiple finished-product manufacturers are affected simultaneously, since they may all source from the same small number of API plants.

Gabapentin Enacarbil Is a Separate Product

If you come across the brand name Horizant, that is not simply another version of gabapentin. Horizant contains gabapentin enacarbil, a prodrug that the body converts into gabapentin after absorption. It was developed by XenoPort (later acquired by Arbor Pharmaceuticals, which is now part of Assertio Therapeutics) specifically to address the absorption limitations of regular gabapentin. Standard gabapentin is absorbed through a saturable transport system in the small intestine, meaning that higher doses are absorbed less efficiently. Gabapentin enacarbil bypasses that bottleneck by using a different absorption pathway, then converting to gabapentin in the body.

Horizant is FDA-approved for restless legs syndrome and postherpetic neuralgia, and it is not interchangeable with regular gabapentin. The dosing, the release profile, and the approved uses differ. Horizant is still under patent protection, so there is no generic gabapentin enacarbil available in the U.S. as of mid-2025. This means patients prescribed Horizant are getting it from one manufacturer, unlike the crowded field for standard gabapentin.

Are All Generic Versions the Same?

This is one of the questions patients ask most often, and the honest answer has some nuance. By regulatory standards, yes, all approved generic versions of gabapentin are considered therapeutically equivalent to the brand-name Neurontin. The FDA requires that generic drugs demonstrate bioequivalence, meaning the generic delivers the same amount of active drug into the bloodstream at roughly the same rate as the brand-name product. A 2011 analysis concluded that generic-to-generic substitution of gabapentin demonstrated bioequivalence with confidence intervals for key absorption measures falling within the standard acceptance range.²

Where it gets more interesting is when you look at the spread across many different generics. A European analysis of 117 oral generic antiseizure products found that gabapentin generics tended to show broader confidence intervals for their bioequivalence estimates and greater variability between individual subjects, compared with generics of other antiseizure drugs. The researchers concluded that the risk of meaningful differences between individual generic gabapentin products was still small and that switching between them was unlikely to cause clinically relevant changes in drug exposure, but they also noted that the potential for variability was greatest for gabapentin among the antiseizure medications studied.³

In practical terms, this means that if your pharmacy switches you from one generic manufacturer to another, the overwhelming likelihood is that you will notice no difference. But among the antiseizure drugs, gabapentin is one of the ones where the generic-to-generic variability is a bit wider than average. Some neurologists prefer to keep epilepsy patients on a consistent manufacturer to avoid even small fluctuations, though this caution applies more to drugs with narrower therapeutic windows than gabapentin.

How Inactive Ingredients Differ

While the active ingredient is chemically the same across all approved generics, the inactive ingredients can vary considerably from one manufacturer to another. These include fillers, binders, coatings, and dyes. You might notice that a gabapentin capsule from Aurobindo looks different from one made by Teva. The color, size, and shape can change when your pharmacy switches suppliers, which understandably makes some people nervous.

For most patients, these differences are cosmetic and clinically meaningless. However, people with specific allergies or sensitivities to certain dyes or fillers (such as lactose, gluten-containing starches, or certain colorants) should pay attention to manufacturer changes. If you have a known sensitivity, your pharmacist can look up the inactive ingredient list for each manufacturer’s version and help you identify which ones to avoid. Some patients also report subjective differences in side effects or effectiveness when they switch generics, though controlled studies have generally not confirmed these perceptions for gabapentin at the population level.

The Global Scale of Gabapentin Production

Gabapentin production is not a niche operation. It is one of the most widely manufactured pharmaceuticals on the planet. A time-series analysis covering 72 countries found that global gabapentinoid sales (which include both gabapentin and the related drug pregabalin) more than doubled from 2012 to 2022, rising by about 115%. The increase was even steeper in developing economies, where sales nearly tripled over the same period.⁴

Several factors drive this growth. Gabapentin is prescribed for epilepsy, neuropathic pain, restless legs syndrome, and a range of off-label uses including anxiety, migraine prevention, and alcohol withdrawal. As clinicians in many countries have sought alternatives to opioids for chronic pain, gabapentin prescribing has surged. This growing demand is why so many manufacturers compete in the space and why production facilities span multiple continents.

Supply Chain Risks and Shortages

With so many manufacturers, you might expect gabapentin to be shortage-proof. It usually is, but not always. The U.S. has experienced intermittent shortages of certain gabapentin dosage forms, particularly the oral solution used in pediatric patients and in adults who cannot swallow capsules. Shortages tend to arise not from a lack of API but from disruptions at the formulation and packaging stage, or from sudden demand spikes.

The FDA maintains a drug shortage database that tracks these events. When a shortage does occur, it can affect one or two manufacturers while others continue to supply the market, so the impact on patients depends partly on which version their pharmacy carries. Pharmacies that rely heavily on a single wholesaler may feel a shortage more acutely than those with diversified sourcing. For patients on gabapentin, the practical takeaway is that keeping a modest buffer of your medication on hand (where your insurance and pharmacy allow it) is reasonable, especially if you take a less common dosage form like the liquid.

Regulatory Oversight Across Countries

Because gabapentin is manufactured in so many countries, the regulatory picture is layered. In the United States, every facility involved in producing a gabapentin product sold domestically must be registered with and periodically inspected by the FDA, regardless of where in the world that facility is located. The FDA inspects API plants in India and China, formulation facilities in Europe, and packaging operations in the Americas. Inspection frequency varies, and the FDA has drawn criticism for the pace at which it can inspect overseas facilities, but the legal requirement is the same for foreign and domestic manufacturers.

In Europe, the European Medicines Agency (EMA) oversees approval of generic products through centralized, mutual recognition, or decentralized procedures. The European analysis of generic antiseizure medications mentioned earlier drew on publicly accessible regulatory assessment reports from these European approval pathways.³ Other major markets, including Japan, Australia, and Canada, have their own regulatory agencies that independently evaluate generic gabapentin products before they can be sold domestically.

What this means for you is that a gabapentin product legally sold in your country has been reviewed and approved by your country’s regulatory authority, regardless of where it was manufactured. That said, the rigor and resources of regulatory agencies differ worldwide, and products sold in less-regulated markets may not meet the same standards as those in the U.S. or Europe.

Gabapentin’s Environmental Footprint

The sheer volume of gabapentin produced globally has an unexpected consequence: the drug is showing up in waterways around the world. Gabapentin passes through the human body largely unchanged, and conventional wastewater treatment plants do not remove it efficiently. A global survey of river water samples found gabapentin in over 40% of the samples tested, spanning rivers on multiple continents. Concentrations in wastewater treatment plant effluent have been measured at levels that concern environmental toxicologists, with some of the highest readings coming from the United Kingdom and Peru.⁵

This is not a manufacturing pollution problem in the traditional sense. The gabapentin in waterways comes primarily from human excretion after therapeutic use, not from factory runoff (though API manufacturing waste is a concern in some regions of India and China). The issue scales directly with how much gabapentin the world consumes, and given the doubling of global sales over the past decade, environmental concentrations are likely rising in parallel. Researchers are still working out whether the levels found in rivers are high enough to affect aquatic organisms over the long term, but the widespread detection itself is a signal that gabapentin’s manufacturing and consumption footprint extends well beyond the pharmacy shelf.

Counterfeit Gabapentin

Because gabapentin has become so widely used and, in some regions, subject to misuse and diversion, counterfeit versions do circulate. Counterfeit gabapentin has been intercepted in illicit drug markets and through unregulated online pharmacies. These products may contain no gabapentin at all, the wrong dose, or dangerous adulterants. The risk is concentrated among people buying gabapentin without a prescription from unverified sources rather than from licensed pharmacies.

In countries where gabapentin has been reclassified as a controlled substance (the United Kingdom made it a Class C controlled substance in 2019, and several U.S. states have added their own scheduling requirements), the restrictions on obtaining it through legitimate channels have, paradoxically, created a small market for counterfeit pills. If you are getting gabapentin through a licensed pharmacy with a valid prescription, counterfeit products are not a realistic concern. The risk is essentially limited to purchases from unregulated sellers, whether in person or online. Licensed pharmacies in regulated countries source from FDA- or EMA-approved supply chains, and the quality controls at that level are robust enough to keep counterfeit products out of legitimate distribution.